

1 **TITLE:**

2 Reconstitution of the Bacterial Glutamate Receptor Channel by Encapsulation of a Cell-Free  
3 Expression System

4

5 **AUTHORS AND AFFILIATIONS:**

6 Kyle J. Loi<sup>1,2#</sup>, Hossein Moghimianavval<sup>3#</sup>, Allen P. Liu<sup>2,3,4,5\*</sup>

7

8 <sup>1</sup>Neuroscience Program, University of Michigan, Ann Arbor, Michigan, USA

9 <sup>2</sup>Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan, USA

10 <sup>3</sup>Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan, USA

11 <sup>4</sup>Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA

12 <sup>5</sup>Department of Biophysics, University of Michigan, Ann Arbor, Michigan, USA

13

14 Email addresses of the co-authors:

15 Kyle J. Loi [kloj@umich.edu](mailto:kloj@umich.edu)

16 Hossein Moghimianavval [mhossein@umich.edu](mailto:mhossein@umich.edu)

17

18 \*Email address of the corresponding author:

19 Allen P. Liu [allenliu@umich.edu](mailto:allenliu@umich.edu)

20

21 #These authors contributed equally to this work

22

23 **SUMMARY:**

24 This protocol describes the inverted emulsion method used to encapsulate a cell-free expression  
25 (CFE) system within a giant unilamellar vesicle (GUV) for the investigation of the synthesis and  
26 incorporation of a model membrane protein into the lipid bilayer.

27

28 **ABSTRACT:**

29 Cell-free expression (CFE) systems are powerful tools in synthetic biology that allow biomimicry  
30 of cellular functions like biosensing and energy regeneration in synthetic cells. Reconstruction of  
31 a wide range of cellular processes, however, requires successful reconstitution of membrane  
32 proteins into the membrane of synthetic cells. While expression of soluble proteins is usually  
33 successful in common CFE systems, reconstitution of membrane proteins in lipid bilayers of  
34 synthetic cells has proven to be challenging. Here, a method for reconstitution of a model  
35 membrane protein, bacterial glutamate receptor (GluR0), in giant unilamellar vesicles (GUVs) as  
36 model synthetic cells based on encapsulation and incubation of the CFE reaction inside synthetic  
37 cells is demonstrated. Utilizing this platform, the effect of substituting N-terminal signal peptide  
38 of GluR0 with proteorhodopsin signal peptide on successful co-translational translocation of  
39 GluR0 into membranes of hybrid GUVs is demonstrated. This method provides a robust procedure  
40 that will allow cell-free reconstitution of various membrane proteins in synthetic cells.

41

42 **INTRODUCTION:**

43 Bottom-up synthetic biology has gained increasing interest over the past decade as an emerging  
44 field with numerous potential applications in bioengineering, drug delivery, and regenerative

45 medicine<sup>1, 2</sup>. Development of synthetic cell as a cornerstone of bottom-up synthetic biology, in  
46 particular, has attracted a wide range of scientific communities due to the promising applications  
47 of synthetic cells as well as their cell-like physical and biochemical properties that facilitate *in vitro*  
48 biophysical studies<sup>3–6</sup>. Synthetic cells are often engineered in cell-sized giant unilamellar vesicles  
49 (GUVs) in which different biological processes are recreated. Reconstitution of cell cytoskeleton<sup>7,</sup>  
50 <sup>8</sup>, light-dependent energy regeneration<sup>9</sup>, cellular communication<sup>10, 11</sup>, and biosensing<sup>12</sup> are  
51 examples of efforts made to reconstruct cell-like behaviors in synthetic cells.

52

53 While some cellular processes rely on soluble proteins, many characteristics of natural cells such  
54 as sensing and communication often utilize membrane proteins including ion channels, receptors,  
55 and transporters. A major challenge in synthetic cell development is reconstitution of membrane  
56 proteins. Although traditional methods of membrane protein reconstitution in lipid bilayers rely  
57 on detergent-mediated purification, such methods are laborious, ineffective for proteins that are  
58 toxic to the expression host, or are often not suited for membrane protein reconstitution in  
59 GUVs<sup>13</sup>.

60

61 An alternative method for protein expression is cell-free expression (CFE) systems. CFE systems  
62 have been a powerful tool in synthetic biology that allow *in vitro* expression of various proteins  
63 using either cell lysate or purified transcription-translation machinery<sup>14</sup>. CFE systems can also be  
64 encapsulated in GUVs, thus allowing compartmentalized protein synthesis reactions that can be  
65 programmed for various applications such as creation of light-harvesting synthetic cells<sup>9</sup> or  
66 mechanosensitive biosensors<sup>15, 16</sup>. Analogous to recombinant protein expression methods,  
67 membrane protein expression is challenging in CFE systems<sup>17</sup>. Aggregation, misfolding, and lack  
68 of post-translational modification in CFE systems are major bottlenecks that hinder successful  
69 membrane protein synthesis using CFE systems. The difficulty of bottom-up membrane protein  
70 reconstitution using CFE systems is due in part to the absence of a complex membrane protein  
71 biogenesis pathway that relies on signal peptides, signal recognition particles, translocons, and  
72 chaperoning molecules. However, recently, multiple studies have suggested that presence of  
73 membranous structures such as microsomes or liposomes during translation promotes successful  
74 membrane protein expression<sup>18–21</sup>. Additionally, Eaglesfield *et al.* and Steinküher *et al.* have found  
75 that inclusion of specific hydrophobic domains known as signal peptides in the N-terminus of the  
76 membrane protein can significantly improve its expression<sup>22, 23</sup>. Altogether, these studies suggest  
77 that the challenge of membrane protein reconstitution in synthetic cells can be overcome if the  
78 protein translation occurs in the presence of the GUV membrane and if proper N-terminal signal  
79 peptide is utilized.

80

81 Here, a protocol for encapsulation of the protein synthesis using recombinant elements (PURE)  
82 CFE reactions for membrane protein reconstitution in GUVs is presented. Bacterial glutamate  
83 receptor<sup>24</sup> (GluR0) as model membrane protein is selected and the effect of its N-terminal signal  
84 peptide on its membrane reconstitution is studied. The effect of proteorhodopsin signal peptide,  
85 which was shown to improve membrane protein reconstitution efficiency by Eaglesfield *et al.*<sup>22</sup>,  
86 is investigated by constructing a mutated variant of GluR0 denoted as PRSP-GluR0 and its  
87 expression and membrane localization with wild type GluR0 (referred to as WT-GluR0 hereafter)  
88 that harbors its native signal peptide is compared. This protocol is based on the inverted emulsion

89 method<sup>25</sup> with modifications that make it robust for CFE encapsulation. In the presented method,  
90 the CFE reactions are first emulsified using a lipid-in-oil solution that generates micron-sized  
91 droplets that contain the CFE system and are stabilized by the lipid monolayer. The emulsion  
92 droplets are then layered on top of an oil-water interface that is saturated with another lipid  
93 monolayer. The emulsion droplets are then forced to travel across the oil-water interface via  
94 centrifugal force. Through this process, the droplets obtain another monolayer, thus generating  
95 a bilayer lipid vesicle. The GUVs containing the CFE reaction are then incubated during which the  
96 membrane protein is expressed and incorporated into the GUV membrane. Although this  
97 protocol is specified for cell-free expression of GluR0, it can be used for cell-free synthesis of other  
98 membrane proteins or different synthetic cell applications such as cytoskeleton reconstitution or  
99 membrane fusion studies<sup>26</sup>.

100

## 101 **PROTOCOL:**

102

### 103 **1. Bulk CFE reactions in the presence of small unilamellar vesicles (SUVs)**

#### 104 **1.1. SUV preparation**

105 NOTE: This step needs to be performed in a fume hood following the safety instructions for  
106 working with chloroform.

107 1.1.1. In a glass vial, prepare 5 mM 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) SUVs  
108 by transferring 76  $\mu$ L of 25 mg/mL POPC stock solution dissolved in chloroform.

109

110 1.1.2. While gently rotating the glass vial, blow a gentle stream of argon into the glass vial to  
111 form a film of dried lipids at the bottom of the vial. Next, transfer the glass vial to a desiccator  
112 with its cap loosely screwed to evaporate excess chloroform.

113

114 1.1.3. Keep the glass vial in the desiccator for 1h. Then add 0.5 mL ultra-pure deionized water to  
115 dissolve the lipid film and vortex for approximately 2 minutes.

116

117 1.1.4. Set up a mini-extrusion apparatus by soaking two filter supports in deionized water and  
118 placing them on each of the internal membrane supports. Then soak a 100 nm polycarbonate  
119 filter and place it in between the two internal membrane supports held together by the extruder  
120 outer casing and the retainer nut. Place this setup in the extruder stand.

121

122 1.1.5. Flush two 1 mL gas-tight syringes 3 times with ultra-pure deionized water.

123

124 1.1.6. Load the sample of lipid-water mix into one of the 1 mL gas-tight syringes and place it in  
125 one end of the mini extruder using the swing arm clips to hold the syringe in place. Insert the  
126 second syringe in the other end of the mini-extruder and make sure it is fully depressed.

127 NOTE: When loading the syringe with the lipid-water mix, ensure there is no air in the syringe  
128 before passing it through the mini-extruder.

129

130 1.1.7. Gently pass the lipid-water mix from the original syringe to the empty syringe through the  
131 mini-extruder apparatus. Repeat this step 11 times to form SUVs. Transfer the SUVs to a 1.5 mL  
132 microcentrifuge tube.

133 NOTE: The SUV solution can be stored at 4 °C for up to two weeks.

134

135 **1.2. CFE reaction assembly**

136 1.2.1. Assemble the CFE reaction by following the cell-free expression protocol provided by the  
137 manufacturer with slight modifications detailed in the following. Mix 10 µL Solution 1 (containing  
138 amino acids, NTPs, tRNAs and substrates for enzymes, and necessary buffer), 1 µL Solution 2  
139 (proteins in 20% glycerol), 2 µL Solution 3 (ribosome (20 µM)), appropriate amount of the DNA  
140 encoding for soluble sfGFP-sfCherry(1-10)<sup>27</sup> (referred to as soluble sfGFP hereafter), WT-GluR0-  
141 sfGFP, or PRSP-GluR0-sfGFP (10-60 ng/1000 base pairs), 1 µL murine RNase inhibitor, and 4 µL 5  
142 mM SUV solution for membrane proteins or 4 µL water for soluble proteins. Bring the reaction  
143 final volume to 20 µL by adding ultra-pure deionized water.

144 NOTE: When assembling the CFE system, all components must be kept on ice. All materials are  
145 temperature-sensitive and can degrade if they reach room temperature.

146

147 **1.3. CFE reaction incubation and monitoring**

148 1.3.1. Transfer the CFE solution to a 96-well conical V-bottom plate. To prevent evaporation  
149 during the course of the reaction, cover the plate using a sealing film.

150

151 1.3.2. Incubate the plate at 37 °C in a plate reader for 4-5 h while monitoring the CFE reaction  
152 by measuring the GFP signal with a gain of 100 at 488/528 excitation/emission wavelengths every  
153 two minutes.

154

155 **2. CFE reactions encapsulated in GUVs**

156 **2.1. Preparation of GUV outer buffer solution**

157 2.1.1. In a 1.5 mL microcentrifuge tube, mix 1.5 µL 1 M spermidine, 37.5 µL 100 mM ATP, 25 µL  
158 100 mM GTP, 12.5 µL 100 mM CTP, 12.5 µL 100 mM UTP, 25 µL 1 M creatine phosphate, 18 µL 1  
159 M magnesium acetate, 93.33 µL 3 M potassium glutamate, 50 µL 1 M HEPES KOH (pH 7.4), 1.15  
160 µL 332 mM folic acid, 100 µL 2 M glucose, and 50 µL from stock solution of 6 mM mixture of  
161 each of the 20 amino acids (prepared by following the protocol described by Sun *et al.*<sup>28</sup>). Bring  
162 the solution final volume to 1 mL by adding ultra-purified deionized water.

163 NOTE: All components must be kept on ice. Add the amino acid mixture at the end to avoid amino  
164 acid depletion<sup>28</sup>.

165 NOTE: The solution can be aliquoted in 330 µL aliquots and stored at -20 °C until use.

166

167 **2.2. Preparation of the lipid-in-oil mixture**

168 NOTE: this step needs to be performed in a fume hood following the safety instructions for  
169 working with chloroform.

170 2.2.1. Under a fume hood, mix 17.3 µL of 25 mg/mL POPC stock solution and 1.08 µL of 50  
171 mg/mL poly(butadiene)-b-poly(ethylene oxide) (PEO-b-PBD) copolymer in a 15 mL glass vial.

172 NOTE: The final lipid-in-oil solution contains 0.5 mM lipid with 95% and 5% POPC and PEO-b-PBD,  
173 respectively. PEO-b-PBD was used to enhance membrane stability during protein expression but  
174 was kept at a low molar ratio to reduce copolymer's tendency to aggregate into micelles separate  
175 from lipid molecules<sup>29, 30</sup>.

176

177 2.2.2. Carefully blow a gentle stream of argon gas into the glass vial while rotating the vial to  
178 evaporate the chloroform.

179

180 2.2.3. Pipette 1.2 mL of light mineral oil to the 15 mL glass vial containing the dried lipids.

181

182 2.2.4. Mix the lipids and oil by vortexing at maximum speed for 10 – 20 seconds. The dissolved  
183 lipid-copolymer mix will look cloudy.

184

185 2.2.5. To ensure that all possible lipid aggregates in the oil are fully dissolved and dispersed  
186 throughout the oil, place the glass vial in an oven at around 50 °C for 20 minutes before vortexing  
187 for an additional 10-20 seconds at maximum speed.

188

### 189 2.3. **CFE reaction assembly and encapsulation**

190 **Fig. 1** depicts a summary of the following steps.

191 2.3.1. Prepare 300  $\mu$ L of the GUV outer solution in a 1.5 mL microcentrifuge tube by mixing 270  
192  $\mu$ L of CFE outer buffer solution prepared in step 2.1, 15  $\mu$ L of 5 M NaCl, and 15  $\mu$ L of 4.5 M KCl.

193 NOTE: At this step, add 0.45  $\mu$ L of 1 M 1,4-dithiothreitol (DTT) to the GUV outer solution.

194 NOTE: The purpose of adding NaCl and KCl is to adjust the outer solution osmolality to match it  
195 with the inner CFE solution. The exact volume of NaCl and KCl depends on the desired osmolality  
196 adjustment. One can add either NaCl or KCl or both to adjust the osmolality.

197

198 2.3.2. Gently pipette 300  $\mu$ L of lipid-in-oil mixture on top of the GUV outer solution.

199 NOTE: When adding the lipid-oil mix, it is important that the oil does not mix with the aqueous  
200 outer solution. After the addition, there should be a visible interface between the lipid-in-oil  
201 mixture and the GUV outer solution.

202

203 2.3.3. Incubate the oil-water interface at room temperature for 2 h to allow the lipid monolayer  
204 to form and stabilize at the interface.

205

206 2.3.4. Meanwhile, follow section 1.2.1 to assemble a CFE reaction containing the plasmid DNA  
207 encoding the membrane protein variants or soluble GFP. Replace the 4  $\mu$ L 5 mM SUV solution or  
208 water with 4  $\mu$ L 1 M sucrose. This reaction will be the GUV inner solution.

209 NOTE: An osmometer was used to measure the osmolality of the inner and outer solutions. The  
210 osmolality of the outer solution was then adjusted accordingly by addition of NaCl or water. The  
211 osmolality of the CFE reaction is typically around 1600 mOsm/Kg.

212 NOTE: Addition of sucrose to the reaction increases the inner solution density, thus allowing the  
213 vesicles to travel across the oil-water interface during the centrifugation step. An alternative to  
214 sucrose is Opti-Prep density gradient solution.

215

216 2.3.5. Add 600  $\mu$ L of lipid-oil mixture to the microcentrifuge tube containing the CFE reaction  
217 and pipette up and down vigorously for ~1 min to emulsify the reaction in lipid-in-oil solution and  
218 form the lipid monolayer around synthetic cells.

219 NOTE: The final solution should not have any bubbles and should look opaque.

220

221 2.3.6. Gently pipette the inner solution emulsion on top of the oil layer in the 1.5 mL  
222 microcentrifuge tube where the oil-water interface was set up.

223 NOTE: Be careful not to disturb or destabilize the interface.

224

225 2.3.7. Centrifuge for 10 minutes at 2000 g at 4 °C.

226 NOTE: The centrifugation speed was optimized for this protocol. Adir *et al.*<sup>31</sup> reported a different  
227 centrifugation speed.

228

229 2.3.8. Once the centrifugation is over, carefully remove the excess oil and outer solution from  
230 the microcentrifuge tube using a pipettor. Remove the outer solution until the remaining volume  
231 is around 100 µL.

232 NOTE: A pellet of GUVs is usually visible at the bottom of the microcentrifuge tube. However, a  
233 lack of a visible pellet does not necessarily mean no GUV yield.

234 NOTE: Instead of using a pipettor, the excess oil on top of the outer solution can be removed by  
235 aspiration.

236 NOTE: It is critical to ensure the lipid-in-oil solution is completely removed. Oil contamination in  
237 GUV solution can cause low-quality images.

238

239 2.3.9. Resuspend the GUV pellet in the remaining 100 µL solution by gently pipetting up and  
240 down. Next, transfer the GUV solution to a clean 96 well clear flat bottom plate to incubate.

241

### 242 3. Encapsulated CFE reaction incubation and imaging

243 3.1. Cover the plate using a sealing film to prevent evaporation. Incubate the plate at 37 °C for 5-  
244 6 h. One can use a plate reader and follow step 1.3.2 to prepare the plate reader for the  
245 incubation step.

246

247 3.2. Once the incubation is over, place the 96 well plate on the imaging stage of an inverted  
248 microscope equipped with an iXON3 EMCCD camera (or a sCMOS camera), DAQ-MX  
249 controlled laser (or an integrated laser combiner system), and a Yokogawa CSU-X1 spinning  
250 disk confocal (or a laser scanning confocal). Focus on any ROI containing GUVs and capture  
251 images at excitation wavelength of 488 nm using a Plan-Apochromat 60 x/1.4 NA objective.

252

253 3.3. Save images of GUVs in .tiff format.

254

255 3.4. Open the images in an image processing software on ImageJ or Fiji. Open the  
256 **Brightness/Contrast** setting panel. Adjust the brightness and contrast to appropriate settings  
257 that make fluorescent proteins visible.

258

259 3.5. If the goal is to compare the signal intensity of different expressed proteins, first stack  
260 individual images of GUVs containing different proteins using **Images to Stack** panel located  
261 under **Image>Stacks** submenu. Then adjust the brightness and contrast of all images using  
262 the **Brightness/Contrast** panel.

263

## 264 REPRESENTATIVE RESULTS

265 Prior to encapsulation of the CFE reactions, two variants of GluR0-sfGFP harboring native and  
266 proteorhodopsin signal peptides (signal peptide sequences presented in **Table S1**) and the soluble  
267 sfGFP were individually expressed in bulk reactions and their expression was monitored by  
268 detecting the sfGFP signal using a plate reader (**Fig. 2A**). Membrane proteins were expressed in  
269 the absence or presence of 100 nm SUVs. Additionally, using a calibration curve that correlates  
270 sfGFP signal to its concentration (**Fig. S1**), concentrations of synthesized proteins were estimated  
271 (**Table S2**). Clearly, soluble sfGFP had the highest expression among all three proteins which  
272 suggests that the expression of membrane proteins imposes a burden on CFE system, thus  
273 slowing down the reaction and lowering its yield. In addition, on average, reactions expressing  
274 membrane proteins in the presence of SUVs showed higher sfGFP signal compared to reactions  
275 lacking SUVs. This observation aligns with the findings of Steinküher *et al.* who showed expression  
276 of membrane proteins reduces the capacity of the CFE systems to produce proteins<sup>23</sup>.  
277 Nevertheless, given the successful demonstration of protein expression in bulk CFE reaction, one  
278 can reason that encapsulated CFE will also synthesize proteins inside GUVs.  
279

280 Next, individual CFE reactions were encapsulated in GUVs using the inverted emulsion method to  
281 express variants of GluR0, namely WT-GluR0 and PRSP-GluR0, and soluble sfGFP. While WT-GluR0,  
282 harboring GluR0 native signal peptide, demonstrated excellent expression and membrane  
283 localization (**Fig. 2B**, left panel), its counterpart, PRSP-GluR0 which has proteorhodopsin N-  
284 terminal signal peptide, did not show similar strong membrane localization. PRSP-GluR0 was  
285 found to be more prone to aggregation and punctate formation (**Fig. 2B**, middle panel).  
286 Expectedly, soluble sfGFP was expressed in GUVs and stayed in the GUV lumen (**Fig. 2B**, right  
287 panel; see **Fig. S2** for images of cohorts of GUVs).  
288

## 289 FIGURE AND TABLE LEGENDS:

290

291 **Figure 1: Experimental steps of inverted emulsion.** (1) Steps 2.3.1 through 2.3.3 of the protocol  
292 are visualized to demonstrate the assembly of the lipid monolayer at the interface of the lipid-oil  
293 mix and outer buffer solution. (2) Visualization of step 2.3.5 of the protocol is shown here to  
294 represent the formation of the lipid monolayer around emulsified droplets encapsulating the  
295 inner CFE solution. (3) Step 2.3.6 of the protocol shows the addition of the monolayer GUVs to  
296 the microcentrifuge tube with the lipid monolayer at the interface of a lipid-oil mix and outer  
297 buffer solution. (4) Step 2.3.7 is depicted here in which centrifugation leads to the formation of a  
298 GUV pellet in the outer solution. (5) Step 2.3.8 is shown here indicating the process of removing  
299 the excess lipid-in-oil mixture and outer solution. (6) Finally, step 2.3.9 is depicted here where the  
300 GUV pellet is resuspended in the outer solution and the GUVs are ready for incubation followed  
301 by imaging.  
302

303 **Figure 2: Protein expression in bulk CFE reactions and in GUVs encapsulating CFE reactions (A)**  
304 Fluorescence readouts of individual bulk CFE reactions expressing WT-GluR0-sfGFP, PRSP-GluR0-  
305 sfGFP, and soluble sfGFP. The soluble sfGFP graph represents the signal from a 2.5  $\mu$ L reaction  
306 (standard reaction volume is 20  $\mu$ L) to avoid oversaturation of the plate reader measurements.  
307 Data is presented as mean  $\pm$  S.D.  $n = 3$ . (B) Left: a representative confocal image of a GUV  
308 encapsulating CFE reaction expressing WT-GluR0-sfGFP. Middle: a representative confocal image

309 of GUVs encapsulating CFE reaction expressing PRSP-GluR0-sfGFP. Right: a representative  
310 confocal image of a GUV encapsulating CFE reaction expressing soluble sfGFP. Scale bars: 10  $\mu$ m.  
311

## 312 **DISCUSSION**

313 Virtually any cellular process that depends on transfer of molecules or information across the cell  
314 membrane like cell signaling or cell excitation requires membrane proteins. Thus, reconstitution  
315 of membrane proteins has become the main bottleneck in realizing various synthetic cell designs  
316 for different applications. Traditional detergent-mediated reconstitution of membrane proteins in  
317 biological membranes requires GUV generation methods such as gentle swelling or  
318 electroformation. Swelling approaches usually produce small-sized vesicles and electroformation  
319 yield significantly drops when complicated solutions, which is often the case when generating  
320 synthetic cells, are encapsulated<sup>32</sup>. Additionally, detergents solubilize the membrane protein and  
321 their removal during the reconstitution process can cause protein misfolding<sup>33, 34</sup>. On the other  
322 hand, the approach presented here relies on co-translational incorporation of the membrane  
323 protein into the lipid bilayer which resembles more the natural protein biogenesis pathway in  
324 cells<sup>22</sup>.

325

326 From a technical point of view, the presented protocol is advantageous to other common  
327 encapsulation methods such as electroformation and continuous droplet interface crossing  
328 encapsulation<sup>7, 8, 35, 36</sup> (cDICE) for easier implementation as the only laboratory equipment  
329 required for GUV generation is a centrifuge. As opposed to electroformation, inverted emulsion  
330 method allows encapsulation of different combinations of molecules with various concentrations.  
331 Additionally, compared to the original inverted emulsion technique<sup>25</sup>, this approach generates  
332 more stable GUVs that are suitable for encapsulation of CFE lysates or PURE systems. The higher  
333 GUV stability is owed to the presence of diblock copolymer in the composition of GUV  
334 membrane<sup>37</sup> as well as the long incubation of oil-water interface that allows the interface to be  
335 saturated with lipid molecules. Lastly, as opposed to microfluidics approaches, the protocol  
336 presented here does not require small channels and tubing. Therefore, the CFE reaction can be  
337 encapsulated as soon as it is assembled and the shorter time of GUV assembly due to lack of flow  
338 and possible clogging prevents premature start of the CFE reaction. While the demonstration of  
339 membrane protein expression in this protocol is exclusive to PUREfrex reactions, one can extend  
340 this method to synthesize proteins using different available CFE systems such as lysate-based  
341 bacterial or mammalian CFE systems.

342

343 The presented approach here has limitations that are caused by the oil-dependent nature of GUV  
344 formation process and the intent to have stable GUVs. This approach is typically longer compared  
345 to other methods such as cDICE or microfluidics methods, due to the long incubation time of the  
346 oil-water interface that is required for interface stabilization and high GUV yield. Additionally, lipid  
347 composition is primarily limited to POPC with small doses of other lipids or block copolymers  
348 while other methods such as electroformation are more suited for incorporation of lipids with  
349 different physical and chemical properties. While the GUV membrane composition in this method  
350 is a mixture of POPC and PBD-PEO to maximize CFE yield, possible variations in GUV membrane  
351 composition can be tested. However, further optimization of the parameters might be required  
352 for other membrane proteins. Since the droplet emulsification occurs through manual pipetting,

353 the GUVs generated via this method are polydisperse and quite heterogeneous in size. Further,  
354 the fact that lipids are dissolved in the organic phase may occasionally cause a layer of oil between  
355 the two leaflets of the GUV membrane or contaminate the imaging chamber with oil that can  
356 detriment image quality. A possible workaround for the challenge of residual oil is to replace  
357 mineral oil with a volatile organic solvent, such as diethyl ether as shown by Tsumoto *et al.*<sup>38</sup>, to  
358 rely on solvent evaporation along with centrifugation during GUV formation.

359

360 While there is no demonstration of channel function in this work, inspired by previous assays  
361 used for probing reconstituted mechano- or light-sensitive channel functionality, a fluorescence  
362 microscopy-based assay is outlined. The opening of GluR0 channel is reported to increase the  
363 membrane conductivity for K<sup>+</sup> ions<sup>24</sup>. Because CFE reactions already contain a high concentration  
364 of K<sup>+</sup>, typical potassium indicators will not be suitable for assessing channel functionality.  
365 However, because potassium influx changes the membrane potential, sensitive membrane  
366 potential indicators such as DiBAC4(3)<sup>22</sup> BeRST 1<sup>39</sup> could report GluR0 activity in the presence of  
367 glutamate.

368

369 Successful reconstitution of membrane proteins in synthetic cells opens up numerous possibilities  
370 for creating synthetic cells with unprecedented abilities that more closely mimic natural cells. A  
371 current major disadvantage of synthetic cells is their inability to reproduce and recycle energy.  
372 However, with light- and chemical-dependent energy regeneration schemes that rely heavily on  
373 membrane proteins, one can envisage long-lasting synthetic cells<sup>40</sup>. Utilizing CFE systems allows  
374 the reconstitution of multiple membrane proteins that can collectively perform certain tasks. For  
375 instance, reconstitution of a ligand-gated ion channel similar to GluR0 described here along with  
376 different voltage-gated ion channels can lead to the construction of an excitable neuron-like  
377 synthetic cell.

378

### 379 **ACKNOWLEDGEMENTS**

380 APL acknowledges support from the National Science Foundation (EF1935265), the National  
381 Institutes of Health (R01-EB030031 and R21-AR080363), and the Army Research Office (80523-  
382 BB)

383

### 384 **DISCLOSURES**

385 The authors declare no conflicts of interest.

386

### 387 **REFERENCES:**

- 388 1. Liu, A.P., Fletcher, D.A. Biology under construction: in vitro reconstitution of cellular  
389 function. *Nat Rev Mol Cell Biol.* **10** (9), 644–650, doi: 10.1038/nrm2746 (2009).
- 390 2. Lin, A.J., Sihorwala, A.Z., Belardi, B. Engineering Tissue-Scale Properties with Synthetic Cells:  
391 Forging One from Many. *ACS Synth. Biol.* **12** (7), 1889–1907, doi:  
392 10.1021/acssynbio.3c00061 (2023).
- 393 3. Powers, J., Jang, Y. Advancing Biomimetic Functions of Synthetic Cells through  
394 Compartmentalized Cell-Free Protein Synthesis. *Biomacromolecules*. doi:  
395 10.1021/acs.biomac.3c00879 (2023).

396 4. Jiang, W. *et al.* Artificial Cells: Past, Present and Future. *ACS Nano*. **16** (10), 15705–15733,  
397 doi: 10.1021/acsnano.2c06104 (2022).

398 5. Groaz, A. *et al.* Engineering spatiotemporal organization and dynamics in synthetic cells.  
399 *WIREs Nanomedicine and Nanobiotechnology*. **13** (3), e1685, doi: 10.1002/wnan.1685  
400 (2021).

401 6. Sharma, B., Moghimianavval, H., Hwang, S.-W., Liu, A.P. Synthetic Cell as a Platform for  
402 Understanding Membrane-Membrane Interactions. *Membranes*. **11** (12), 912, doi:  
403 10.3390/membranes11120912 (2021).

404 7. Bashirzadeh, Y. *et al.* Actin crosslinker competition and sorting drive emergent GUV size-  
405 dependent actin network architecture. *Commun Biol.* **4** (1), 1–11, doi: 10.1038/s42003-021-  
406 02653-6 (2021).

407 8. Bashirzadeh, Y., Moghimianavval, H., Liu, A.P. Encapsulated actomyosin patterns drive cell-  
408 like membrane shape changes. 2021.10.20.465228, doi: 10.1101/2021.10.20.465228  
409 (2021).

410 9. Berhanu, S., Ueda, T., Kuruma, Y. Artificial photosynthetic cell producing energy for protein  
411 synthesis. *Nat Commun.* **10** (1), 1325, doi: 10.1038/s41467-019-09147-4 (2019).

412 10. Ji, Y., Chakraborty, T., Wegner, S.V. Self-Regulated and Bidirectional Communication in  
413 Synthetic Cell Communities. *ACS Nano*. **17** (10), 8992–9002, doi: 10.1021/acsnano.2c09908  
414 (2023).

415 11. Moghimianavval, H., Loi, K.J., Hwang, S.-W., Bashirzadeh, Y., Liu, A.P. Light-based juxtacrine  
416 signaling between synthetic cells. 2024.01.05.574425, doi: 10.1101/2024.01.05.574425  
417 (2024).

418 12. Boyd, M.A., Thavarajah, W., Lucks, J.B., Kamat, N.P. Robust and tunable performance of a  
419 cell-free biosensor encapsulated in lipid vesicles. *Science Advances*. **9** (1), eadd6605, doi:  
420 10.1126/sciadv.add6605 (2023).

421 13. Schneider, B. *et al.* Membrane Protein Expression in Cell-Free Systems. *Heterologous  
422 Expression of Membrane Proteins: Methods and Protocols*. 165–186, doi: 10.1007/978-1-  
423 60761-344-2\_11 (2010).

424 14. Noireaux, V., Liu, A.P. The New Age of Cell-Free Biology. *Annual Review of Biomedical  
425 Engineering*. **22** (1), 51–77, doi: 10.1146/annurev-bioeng-092019-111110 (2020).

426 15. Majumder, S., Garamella, J., Wang, Y.-L., DeNies, M., Noireaux, V., Liu, A.P. Cell-sized  
427 mechanosensitive and biosensing compartment programmed with DNA. *Chem. Commun.*  
428 **53** (53), 7349–7352, doi: 10.1039/C7CC03455E (2017).

429 16. Poddar, A. *et al.* Membrane stretching activates calcium permeability of a putative channel  
430 Pkd2 during fission yeast cytokinesis. *MBoC*. **33** (14), ar134, doi: 10.1091/mbo.22-07-0248  
431 (2022).

432 17. Sachse, R., Dondapati, S.K., Fenz, S.F., Schmidt, T., Kubick, S. Membrane protein synthesis in  
433 cell-free systems: From bio-mimetic systems to bio-membranes. *FEBS Letters*. **588** (17),  
434 2774–2781, doi: 10.1016/j.febslet.2014.06.007 (2014).

435 18. Dondapati, S.K., Lübberding, H., Zemella, A., Thoring, L., Wüstenhagen, D.A., Kubick, S.  
436 Functional Reconstitution of Membrane Proteins Derived From Eukaryotic Cell-Free  
437 Systems. *Frontiers in Pharmacology*. **10**, at  
438 <<https://www.frontiersin.org/articles/10.3389/fphar.2019.00917>> (2019).

439 19. Majumder, S. *et al.* In Vitro Synthesis and Reconstitution Using Mammalian Cell-Free Lysates  
440 Enables the Systematic Study of the Regulation of LINC Complex Assembly. *Biochemistry*. **61**  
441 (14), 1495–1507, doi: 10.1021/acs.biochem.2c00118 (2022).

442 20. Niwa, T. *et al.* Comprehensive study of liposome-assisted synthesis of membrane proteins  
443 using a reconstituted cell-free translation system. *Sci Rep.* **5** (1), 18025, doi:  
444 10.1038/srep18025 (2015).

445 21. Moghimianaval, H., Hsu, Y.-Y., Groaz, A., Liu, A.P. In Vitro Reconstitution Platforms of  
446 Mammalian Cell-Free Expressed Membrane ProteinsMembrane proteins. *Cell-Free Gene*  
447 *Expression: Methods and Protocols*. 105–120, doi: 10.1007/978-1-0716-1998-8\_6 (2022).

448 22. Eaglesfield, R., Madsen, M.A., Sanyal, S., Reboud, J., Amtmann, A. Cotranslational  
449 recruitment of ribosomes in protocells recreates a translocon-independent mechanism of  
450 proteorhodopsin biogenesis. *iScience*. **24** (5), 102429, doi: 10.1016/j.isci.2021.102429  
451 (2021).

452 23. Steinküher, J., Peruzzi, J.A., Krüger, A., Jacobs, M.L., Jewett, M.C., Kamat, N.P. Improving cell-  
453 free expression of membrane proteins by tuning ribosome co-translational membrane  
454 association and nascent chain aggregation. 2023.02.10.527944, doi:  
455 10.1101/2023.02.10.527944 (2023).

456 24. Chen, G.-Q., Cui, C., Mayer, M.L., Gouaux, E. Functional characterization of a potassium-  
457 selective prokaryotic glutamate receptor. *Nature*. **402** (6763), 817–821, doi: 10.1038/45568  
458 (1999).

459 25. Pautot, S., Frisken, B.J., Weitz, D.A. Production of Unilamellar Vesicles Using an Inverted  
460 Emulsion. *Langmuir*. **19** (7), 2870–2879, doi: 10.1021/la026100v (2003).

461 26. Hsu, Y.-Y. *et al.* Calcium-triggered DNA-mediated membrane fusion in synthetic cells.  
462 *Chemical Communications*. **59** (57), 8806–8809, doi: 10.1039/D3CC02204H (2023).

463 27. Moghimianaval, H. *et al.* Engineering Functional Membrane–Membrane Interfaces by  
464 InterSpy. *Small*. **19** (13), 2202104, doi: 10.1002/smll.202202104 (2023).

465 28. Sun, Z.Z., Hayes, C.A., Shin, J., Caschera, F., Murray, R.M., Noireaux, V. Protocols for  
466 Implementing an Escherichia coli Based TX-TL Cell-Free Expression System for Synthetic  
467 Biology. *JoVE (Journal of Visualized Experiments)*. (79), e50762, doi: 10.3791/50762 (2013).

468 29. Jacobs, M.L., Boyd, M.A., Kamat, N.P. Diblock copolymers enhance folding of a  
469 mechanosensitive membrane protein during cell-free expression. *Proceedings of the*  
470 *National Academy of Sciences*. **116** (10), 4031–4036, doi: 10.1073/pnas.1814775116 (2019).

471 30. Kostarelos, K., Tadros, Th.F., Luckham, P.F. Physical Conjugation of (Tri-) Block Copolymers to  
472 Liposomes toward the Construction of Sterically Stabilized Vesicle Systems. *Langmuir*. **15**  
473 (2), 369–376, doi: 10.1021/la971052d (1999).

474 31. Adir, O. *et al.* Preparing Protein Producing Synthetic Cells using Cell Free Bacterial Extracts,  
475 Liposomes and Emulsion Transfer. *J Vis Exp.* **158** (158), e60829, doi: 10.3791/60829 (2020).

476 32. van de Cauter, L., van Buren, L., Koenderink, G.H., Ganzinger, K.A. Exploring Giant  
477 Unilamellar Vesicle Production for Artificial Cells – Current Challenges and Future Directions.  
478 *Small Methods*. **n/a** (n/a), 2300416, doi: 10.1002/smtd.202300416.

479 33. Seddon, A.M., Curnow, P., Booth, P.J. Membrane proteins, lipids and detergents: not just a  
480 soap opera. *Biochimica et Biophysica Acta (BBA) - Biomembranes*. **1666** (1), 105–117, doi:  
481 10.1016/j.bbamem.2004.04.011 (2004).

482 34. Guo, Y. Detergent-free systems for structural studies of membrane proteins. *Biochemical*  
483 *Society Transactions*. **49** (3), 1361–1374, doi: 10.1042/BST20201080 (2021).

484 35. Bashirzadeh, Y., Wubshet, N., Litschel, T., Schwille, P., Liu, A.P. Rapid Encapsulation of  
485 Reconstituted Cytoskeleton Inside Giant Unilamellar Vesicles. *J Vis Exp.* (177), doi:  
486 10.3791/63332 (2021).

487 36. Hwang, S.-W. *et al.* Hybrid Vesicles Enable Mechano-Responsive Hydrogel Degradation.  
488 *Angewandte Chemie International Edition*. **62** (41), e202308509, doi:  
489 10.1002/anie.202308509 (2023).

490 37. Rideau, E., Dimova, R., Schwille, P., Wurm, F.R., Landfester, K. Liposomes and polymersomes:  
491 a comparative review towards cell mimicking. *Chem. Soc. Rev.* **47** (23), 8572–8610, doi:  
492 10.1039/C8CS00162F (2018).

493 38. Tsumoto, K., Hayashi, Y., Tabata, J., Tomita, M. A reverse-phase method revisited: Rapid  
494 high-yield preparation of giant unilamellar vesicles (GUVs) using emulsification followed by  
495 centrifugation. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. **546**, 74–  
496 82, doi: 10.1016/j.colsurfa.2018.02.060 (2018).

497 39. Huang, Y.-L., Walker, A.S., Miller, E.W. A Photostable Silicon Rhodamine Platform for Optical  
498 Voltage Sensing. *J. Am. Chem. Soc.* **137** (33), 10767–10776, doi: 10.1021/jacs.5b06644  
499 (2015).

500 40. Bailoni, E., Partipilo, M., Coenradij, J., Grundel, D.A.J., Slotboom, D.J., Poolman, B. Minimal  
501 Out-of-Equilibrium Metabolism for Synthetic Cells: A Membrane Perspective. *ACS Synth.*  
502 *Biol.* **12** (4), 922–946, doi: 10.1021/acssynbio.3c00062 (2023).

503